TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Milestone Pharmaceuticals Inc.
Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

Milestone Pharmaceuticals received FDA approval for CARDAMYST, the first self-administered nasal spray for treating paroxysmal supraventricular tachycardia (PSVT) in adults, offering a novel at-home treatment option for over 2 million Americans with this heart condition.

Insights
MIST   positive

Company achieved significant milestone with first FDA-approved product, demonstrating successful drug development and potential market expansion